O002/#43 Randomized phase 3 study of lenvatinib plus pembrolizumab for advanced endometrial cancer (aec): subgroup analysis of patients with DNA mismatch repair deficient (DMMR) tumors
2021
Keywords:
-
Correction
-
Source
-
Cite
-
Save
-
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI